Showing 3621-3630 of 3946 results for "".
- Curcumin Nanoparticles Prevent Infections in Healing Woundshttps://practicaldermatology.com/news/20140922-curcumin_nanoparticles_prevent_infections_in_healing_wounds/2459114/Curcumin nanoparticles (curc-np) inhibit in vitro growth of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in dose-dependent fashion, and inhibits MRSA growth and enhances wound healing in an in vivo murine wound model, new research in the journal
- Dermira Completes $51 Million Financing and Expands Management Team and Board of Directorshttps://practicaldermatology.com/news/20140821-dermira_completes_51_million_financing_and_expands_management_team_and_board_of_directors/2459139/Dermira, a specialty biopharmaceutical focused on dermatology, completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock S
- 'Sun Safe' Study: Children Seek Shade if Availablehttps://practicaldermatology.com/news/20140812-sun_safe_study_children_seek_shade_if_available/2459147/A new study by the founder of Sun Safe Soccer reveals nearly two-thirds of children will use shade tents during soccer breaks without any prompting from coaches. The study, published in JAMA Dermatology, was conducted by Ian Maher, M.D., who developed the Sun Safe Soccer skin cancer preve
- National Call-to-Action on Skin Cancer Preventionhttps://practicaldermatology.com/news/20140806-national_call-to-action_on_skin_cancer_prevention/2459152/The American Academy of Dermatology Association (AADA) recently joined with the U.S. Department of Health and Human Services' (HHS) Office of the Surgeon General and Centers for Disease Control and Prevention (CDC) to issue a national call-to-action on skin cancer prevention. T
- MELA Sciences Reports the Closing of Its Private Placementhttps://practicaldermatology.com/news/20140728-mela_sciences_reports_the_closing_of_its_private_placement/2459156/IRVINGTON, N.Y., July 25, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, announced today that it has closed i
- Study: Dermatologists Preferred for Skin Cancer Evaluation and Treatmenthttps://practicaldermatology.com/news/20140722-study_dermatologists_preferred_for_skin_cancer_evaluation_and_treatment/2459161/Dermatologists are overwhelmingly the preferred health care provider for evaluating and treating skin cancer, according to a study published in the June issue of Dermatologic Surgery. In an online survey, respondents were asked their choice for evaluating a worrisome lesion on the face and for remov
- New Patient Education Service from Vivacare Helps Medical Professionals Deliver Health Education at the Point of Carehttps://practicaldermatology.com/news/20140716-new_patient_education_service_from_vivacare_helps_medical_professionals_deliver_health_education_at_the_point_of_care/2459166/Vivacare, a leading provider of patient education services for physicians, today announced a major upgrade to its free, web-based service and the opportunity for physician assistants, nurse practitioners and other medical professionals to enroll. In just minutes, physicians and other medical pr
- LEO Pharma and KLOX Technologies Strike Global Dermatology Dealhttps://practicaldermatology.com/news/20140715-leo_pharma_and_klox_technologies_strike_global_dermatology_deal/2459167/LEO Pharma A/S and KLOX Technologies Inc. have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX's BioPhotonic technology platform in dermatology, which includes a CE-approved treatment for moderate to sever
- Trevi Therapeutics Initiates Pivotal Study of Nalbuphine ER in Uremic Pruritushttps://practicaldermatology.com/news/20140714-trevi_therapeutics_initiates_pivotal_study_of_nalbuphine_er_in_uremic_pruritus/2459171/Trevi Therapeutics recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus. Trevi's President and Chief Executive Officer, Jennife
- Resident Grants Available for Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20140701-resident_grants_available_for_cosmetic_surgery_forum/2459183/The Cosmetic Surgery Forum 2014, jointly sponsored by the Dulaney Foundation, Practical Dermatology® magazine and Cosmetic Surgery Forum, LLC, will take place December 3 through December 6, 2014 at The Palazzo Hotel Resort & Casino i